Seborrheic Dermatitis Global Market Report 2024

The seborrheic dermatitis market size has grown rapidly in recent years. It will grow from $2.46 billion in 2023 to $2.76 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth observed during the historic period can be attributed to several factors, including advancements in diagnosis and increased awareness, a growing aging population, lifestyle factors influencing dermatological conditions, advancements in dermatology, and consumer preferences favoring cosmetic solutions.

The seborrheic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $4.14 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The anticipated growth in the forecast period can be attributed to a heightened focus on natural and herbal products, supportive regulatory measures for new therapies, global health preparedness initiatives, and increased patient advocacy and support. Major trends expected during the forecast period include the integration of dermatological technologies, ongoing research on the role of the microbiome in dermatology, the development of customized treatment plans, the widespread adoption of telemedicine and e-health solutions, and continuous technological innovations in skincare.

The prevalence of dermatological diseases is on the rise, contributing to the anticipated growth of the seborrheic dermatitis market. Dermatological diseases encompass various medical conditions that affect the skin, hair, nails, and mucous membranes. Treating these conditions not only provides relief from discomfort but also improves skin appearance and helps prevent complications such as infections or scarring, thereby significantly enhancing affected individuals' overall quality of life. For instance, as per data from the National Psoriasis Foundation in December 2022, an estimated 125 million people worldwide, constituting approximately 2-3% of the global population, were affected by psoriasis - a type of dermatological disease. In the United States alone, over 8 million individuals were reported to have psoriasis in 2022. Hence, the increasing prevalence of dermatological diseases is expected to fuel the growth of the seborrheic dermatitis market.

The seborrheic dermatitis market is expected to witness expansion driven by the escalating healthcare expenditure. This expenditure refers to the total spending on healthcare-related goods and services within a healthcare system or economy. For seborrheic dermatitis, healthcare expenditure encompasses costs linked with diagnosis, management, and treatment. It encompasses various medical services, therapies, and supportive systems allocated to patients affected by the condition. For example, according to the Canadian Institute for Health Information in November 2022, healthcare expenditure increased by 8% - amounting to $331 billion in 2022 compared to 7.6% in 2021. Consequently, the surge in healthcare expenditure is a significant driver fueling the growth of the seborrheic dermatitis market.

The market's growth may face obstacles due to the high cost associated with pharmacologic treatment options. The elevated expenses linked to these treatments create a barrier for numerous patients, sparking discussions about healthcare affordability, insurance coverage, and initiatives aimed at reducing drug prices. The considerable cost of pharmacologic treatments poses challenges for individuals affected by seborrheic dermatitis, impacting their access to suitable remedies and potentially leading to dissatisfaction with their ongoing treatment regimens. For instance, CostHelper Inc. reported in 2023 that prescription-strength antifungal and anti-inflammatory medications could surpass the costs of mild corticosteroids, while over-the-counter shampoos and topical therapies for seborrheic dermatitis often amount to less than $20 per month. Thus, the high cost of pharmacologic treatment options acts as a hindrance to the seborrheic dermatitis market's growth.

Leading companies in the seborrheic dermatitis market are dedicating efforts to pioneer innovative and more efficacious medical therapies, such as roflumilast foam, to drive market revenues. Roflumilast foam represents a novel, daily-use topical treatment specifically designed for inflammatory skin conditions in hair-bearing areas such as the scalp, face, and trunk. For example, Arcutis Biotherapeutics Inc., a US-based medical dermatology company, introduced roflumilast foam 0.3% in April 2023 as the first topical drug with a unique mechanism of action for seborrheic dermatitis approved by the Food and Drug Administration (FDA) in over two decades. This investigational formulation is a once-daily, topical treatment containing a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor, designed to address inflammatory dermatoses, particularly in hair-bearing areas, for individuals aged nine years and older.

In September 2022, Arcutis Biotherapeutics Inc., a medical dermatology company based in the United States, successfully acquired Ducentis BioTherapeutics Ltd. for an approximate sum of $30 million. This strategic move by Arcutis Biotherapeutics aims to enhance its product pipeline and capitalize on the specialized expertise and capabilities of Ducentis BioTherapeutics. The acquisition is geared towards the development, manufacturing, and commercialization of therapies that address unmet needs in the field of dermatology. Ducentis BioTherapeutics Ltd., based in the United Kingdom, is a biotechnology company known for its focus on innovative treatments for various dermatological conditions, including psoriasis, atopic dermatitis, seborrheic dermatitis, and hand eczema.

Major companies operating in the seborrheic dermatitis market report are Pfizer Inc., Johnson and Johnson, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Co, Abbott Laboratories, GlaxoSmithKline Plc, Acella Pharmaceuticals LLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Galderma S.A., Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Monarch Pharmachem, Alliance Pharma plc, Genentech Inc., Zydus Group, Arcutis Biotherapeutics Inc.

North America was the largest region in the seborrheic dermatitis market in 2023. The regions covered in the seborrheic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the seborrheic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The seborrheic dermatitis market consists of revenues earned by entities by providing services, including photodynamic therapy and light therapy combinations. The market value includes the value of related goods sold by the service provider or included within the service offering. The seborrheic dermatitis market also includes sales of topical steroids, and calcineurin inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main types of treatment for seborrheic dermatitis encompass anti-inflammatory, antifungal, corticosteroid lotions, sulfur products, and others. Anti-inflammatory treatments are designed to alleviate inflammation, a common symptom in various dermatological conditions. Diagnoses may involve physical examination, biopsy, and other methods, and treatment can take various dosage forms such as creams, shampoos, ointments, gels, among others. Administration routes may include oral, topical, parenteral, and others. These treatments find application across diverse end-users, including hospitals, specialty clinics, homes, and other healthcare settings.

The seborrheic dermatitis market research report is one of a series of new reports that provides seborrheic dermatitis market statistics, including seborrheic dermatitis industry global market size, regional shares, competitors with a seborrheic dermatitis market share, detailed seborrheic dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the seborrheic dermatitis industry. This seborrheic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.